C12N 2740/16071
Demonstrated in vivo effect
C12N2740/16071 (Demonstrated in vivo effect) appears on 55 US grants and 94 published applications in this corpus.
Search patents in C12N- Granted patents
- 55
- Published applications
- 94
- Assignees
- 70
- Inventors
- 152
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 4 |
| 2010 | 0 | 3 |
| 2011 | 1 | 1 |
| 2012 | 1 | 2 |
| 2013 | 1 | 4 |
| 2014 | 2 | 4 |
| 2015 | 4 | 5 |
| 2016 | 4 | 7 |
| 2017 | 8 | 11 |
| 2018 | 6 | 5 |
| 2019 | 2 | 8 |
| 2020 | 5 | 5 |
| 2021 | 5 | 11 |
| 2022 | 3 | 4 |
| 2023 | 4 | 6 |
| 2024 | 2 | 4 |
| 2025 | 1 | 4 |
| 2026 | 4 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- KIR 7.1 gene therapy vectors and methods of using the same18 Aug 2026US 12,709,760 B2Wisconsin Alumni Research Foundation
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Modified immunogenic proteins10 Mar 2026US 12,569,551 B2International AIDS Vaccine Initiative
- Non-invasive agent applicator13 Jan 2026US 12,521,540 B2MuPharma Pty Ltd
- Compositions and methods for treating cancer with DuoCARs22 Jul 2025US 12,365,718 B2Lentigen Technology, Inc.
- Modified immunogenic proteins6 Aug 2026US 2026/0224689 A1International AIDS Vaccine Initiative
- Particles displaying adhesion-molecule fusions25 Jun 2026US 2026/0176651 A1Umoja Biopharma, Inc.
- Compositions of nucleic acid nanostructures for vaccines and methods of use thereof25 Dec 2025US 2025/0387466 A1Massachusetts Institute of Technology
- Compositions and Methods for Treating Cancer with DuoCARs4 Dec 2025US 2025/0367291 A1Lentigen Technology, Inc.
- Epitope focusing by variable effective antigen surface concentration8 May 2025US 2025/0145668 A1Centivax, Inc.
Most cited
By later US patents
- Mammalian codon optimized nucleotide sequence that encodes a variant opsin polypeptide derived from Natromonas pharaonis (NpHR)40US 9,284,353 B2The Board of Trustees of the Leland Stanford Junior University · 2016
- Pharmaceutical compositions containing 1-methyl-D-tryptophan14US 8,232,313 B2Georgia Health Sciences University · 2012
- Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities12US 7,598,287 B2Medical College of Georgia Research Institute, Inc. · 2009
- Multi-clade chimeric immunogens derived from highly conserved regions of the human immunodeficiency virus type 1 (HIV-1) consensus proteome11US 7,981,430 B2Medical Research Council · 2011
- Optogenetic method for generating an inhibitory current in a mammalian neuron10US 9,757,587 B2The Board of Trustees of the Leland Stanford Junior University · 2017